Background
: Increasing data has shown that ovarian cancer patients carrying BRCA1 and BRCA2 mutations, both somatic and germline, experience a survival advantage and are more sensitive to DNA damaging agents such as platinum and PARP inhibitors. We aim to identify BRCA1 and 2 mutations in various histological subtypes of epithelial ovarian cancer (EOC) tumor samples and to identify molecular differences in EOCs with or without BRCA1 or 2 mutations.